Angiotensinogen (AGT) is the precursor of active vasoconstrictive octapeptide angiotensin II
(Ang II) in the renin-angiotensin-aldosterone system. Blocking the AGT-converting enzymes …

Small interfering RNAs (siRNAs) targeting hepatic angiotensinogen (Agt) may provide long-
lasting antihypertensive effects, but the optimal approach remains unclear. Here, we …

Small interfering RNA (siRNA) targeting liver angiotensinogen (AGT) lowers blood pressure,
but its effectiveness in hypertensive chronic kidney disease is unknown. Considering that …

Background A single dose of small interfering RNA (siRNA) targeting liver angiotensinogen
eliminates hepatic angiotensinogen and lowers blood pressure. Angiotensinogen …

Angiotensinogen (AGT) has been shown to have a role in cardiac hypertrophy, while
depletion of the AGT gene in spontaneously hypertensive rats (SHR) has not been …

Background and Purpose Small interfering RNA (siRNA) targeting liver angiotensinogen
lowers blood pressure, but its effects in hypertensive diabetes are unknown. Experimental …

Blood pressure management involves antihypertensive therapies blocking the renin-
angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the …

Dear Editor We read with great interest the article by Uijl et al.[1] who reported that liver-
directed small interfering RNA (siRNA) targeted to angiotensinogen (AGT) does not reverse …

Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …

Hypertension remains the leading cause of cardiovascular disease and premature death
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …